Skip to main content

Nukkleus Inc

For the period ended Jun 30, 2024. Filed Sep 11, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Sep 11, 2024

DFNS$1.95-3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

The following exhibits are incorporated into this Form 10-Q Quarterly Report:

Incorporated by Reference
ExhibitDescriptionSchedule/ FormExhibitsFiling Date
2.1#Amended and Restated Agreement and Plan of Merger dated as of June 23, 2023, by and among Nukkleus and Brilliant.Form 8-K2.1June 26, 2023
2.2#First Amendment to Amended and Restated Agreement and Plan of Merger dated as of November 1, 2023, by and among Nukkleus and Brilliant.Form 8-K2.2November 2, 2023
3.1Amended and Restated Certificate of Incorporation of Nukkleus Inc. (f/k/a Brilliant Acquisition Corp.)Form 8-K3.2January 2, 2024
3.2Bylaws of Nukkleus Inc.Form 8-K3.3January 2, 2024
4.1Senior Unsecured Promissory Note dated June 11, 2024 issued to X Group Fund of FundsForm 8-K4.1June 17, 2024
4.2Common Stock Purchase Warrant issued to X Group Fund of FundsForm 8-K4.2June 17, 2024
4.3Senior Unsecured Promissory Note dated August 1, 2024 issued to East Asia Technology Investments LimitedForm 8-K4.1August 5, 2024
4.4Common Stock Purchase Warrant issued to East Asia Technology Investments LimitedForm 8-K4.2August 5, 2024
10.1*Nukkleus 2023 Incentive Award Plan.Form 8-K10.1January 2, 2024
10.2Form of Registration Rights Agreement by and among Nukkleus, Brilliant and certain stockholders.Form 8-K10.3June 26, 2023
10.3Form of Lock-Up Agreement by and among Nukkleus, Brilliant and certain stockholders.Form 8-K10.2June 26, 2023
10.4General Service Agreement between Nukkleus Limited and FML Malta Limited dated May 24, 2016Form 10-K10.4July 12, 2024
10.5General Service Agreement between Nukkleus Limited and FXDirectDealer LLC dated May 24, 2016Form 10-K10.5July 12, 2024
10.6Amendment No. 1 dated June 3, 2016 to the General Service Agreement between Nukkleus Limited and FXDD Trading LimitedForm 10-K10.6July 12, 2024
10.7Amendment dated October 17, 2017 of that certain General Service Agreement between Nukkleus Limited and FML Malta LimitedForm 10-K10.7July 12, 2024
10.8Letter Agreement entered between FML Malta Ltd., FXDD Malta Limited and Nukkleus LimitedForm 10-K10.8July 12, 2024
10.9Settlement Agreement and Stipulation dated May 28, 2024 by and between Nukkleus Inc. and Silverback Capital CorporationForm 8-K10.1June 4, 2024
10.10Restructuring Agreement dated June 11, 2024 between Nukkleus Inc. and X Group Fund of FundsForm 8-K10.1June 17, 2024
10.11Voting Agreement dated June 11, 2024 between Nukkleus Inc. and X Group Fund of FundsForm 8-K10.2June 17, 2024
31.1Rule 13a-14(a) Certification of the Chief Executive Officer and Principal Financial Officer
32.1Section 1350 Certification of Chief Executive Officer and Principal Financial Officer
101.INSInline XBRL Instance Document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
*Indicates management contract or compensatory plan or arrangement.
#Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.